Opinion|Videos|January 22, 2025
ADCs in HER2-Low Breast Cancer: Insights From DESTINY-Breast04, TROPiCS-02, and TROPION-Breast02
Panelists discuss how clinical trials like DESTINY-Breast04, TROPiCS-02, and TROPION-Breast01 have revolutionized treatment options for HER2-low advanced breast cancer by validating novel targeted therapies and antibody-drug conjugates.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Provide a brief overview of the treatment landscape for HER2-low advanced breast cancer. Briefly highlight key insights from pivotal trials that have helped shape this treatment space:
- DESTINY-Breast04
- TROPiCS-02
- TROPION-Breast01
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Gedatolisib plus fulvestrant, with or without palbociclib, has been added to the NCCN guidelines for select patients with previously treated breast cancer.
Dato-DXd was approved in the European Union as monotherapy for patients with first-line metastatic TNBC who are not candidates for immunotherapy.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
2
FDA Flashback: Breast Cancer Decisions and News From July 2026
3
FDA Grants Fast Track Designation to BI-1808 Plus Pembrolizumab in Ovarian Cancer
4
Dr Wong on the FDA Approval of Vusolimogene Oderparepvec-wtpg Plus Nivolumab in Melanoma
5